Why most peptides are injected

A peptide is a chain of amino acids, and the gastrointestinal tract is built to dismantle exactly that. Any peptide swallowed as an unmodified sequence meets a set of barriers that evolution designed to break down dietary protein. That is why the overwhelming majority of peptide medicines in the UK are given by injection — and why 'oral peptide' is a claim that needs evidence, not a category.

There are exceptions. A small number of peptides and peptide-class medicines are licensed for oral use, and each works because the molecule has been engineered, or paired with a chemical enhancer, to survive a route it would not otherwise cross.

The four barriers

  1. Proteolysis. Proteases in the stomach and small intestine cleave peptide bonds. A short peptide can be reduced to fragments before it reaches the intestinal wall.
  2. Permeability. Peptides are large, polar and heavily hydrogen-bonded. The intestinal epithelium is a lipid barrier, and molecules in this class cross it poorly — often with absolute bioavailability in the very low single digits, if at all.
  3. First-pass metabolism. What does cross the gut wall drains into the portal vein and passes through the liver before reaching the systemic circulation, where further degradation can occur.
  4. Size and charge. As chain length rises, so does susceptibility to enzymatic attack; as polarity rises, passive absorption falls. The two constraints pull against each other.

The routes used instead

  • Subcutaneous injection — the dominant route for peptide therapeutics, and the reason depot and half-life-engineering strategies matter (see the Peptide Data explainer on lipidation, PEGylation and albumin binding).
  • Intravenous or infusion — used where precise systemic exposure is needed.
  • Nasal — exploited by a small number of peptides, such as desmopressin, where the molecule is small enough and stable enough to cross the nasal mucosa.
  • Inhaled — investigated repeatedly and, outside a narrow set of products, rarely delivers reproducible systemic exposure.
  • Intrathecal — used for peptides that must reach the central nervous system directly, such as the conotoxin ziconotide.

The exceptions: how a few peptides are made to work orally

The oral products that exist did not ignore the barriers — they were built to defeat one or more of them.

  • An absorption enhancer. Oral semaglutide is co-formulated with the carrier SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC raises local pH and promotes transcellular absorption across the gastric epithelium, which allows a small fraction of the peptide to reach the circulation. Absolute bioavailability remains low — measured in fractions of a percent — but it is sufficient to be therapeutically useful when paired with the right dose form.
  • A permeation enhancer in a capsule. Oral octreotide capsules pair the somatostatin analogue with a permeation enhancer to increase intestinal uptake. This product holds a US approval; it does not hold a UK marketing authorisation, and that difference is exactly the point about jurisdiction.
  • Acting from inside the gut lumen. Some oral peptides are designed not to be absorbed at all. The guanylate cyclase-C agonists linaclotide and plecanatide are licensed to act at the luminal surface of the intestine, so systemic absorption is neither needed nor intended.
  • A molecule that is not a peptide. Orforglipron, an oral GLP-1 receptor agonist, is a small molecule rather than a peptide — a design choice that sidesteps the peptide-absorption problem entirely rather than solving it.

What this means for research compounds

For a compound sold 'for research use only', a delivery claim is a claim like any other, and it carries no regulatory weight.

  • Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a peptide presented for a medicinal purpose is a medicinal product whatever route is described; the 'research use only' label does not convert it into something else.
  • A licensed oral peptide product is licensed as that product, for those indications. Its existence does not licence the same peptide bought elsewhere, at a different dose form, or for a different purpose.
  • An unmodified research peptide swallowed as-is bypasses none of the four barriers above. Where a study reports oral activity in an animal model, that is a different question from whether a human oral product exists.

Peptide Data does not provide dosing, reconstitution or administration guidance for any compound. This article describes pharmacology and regulation, not use.

Where the evidence is thin

Enhancer-based oral delivery is a narrow, product-specific achievement, not a general property of the peptide class. Bioavailability figures for individual products vary with formulation, food and dose form, and should be read from the product's own regulatory documentation rather than generalised. Claims that a research peptide is 'orally available' should be treated as unevidenced unless a specific, characterisable formulation and its pharmacokinetic data are named.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.